L Samalin1, M Abbar2, P Courtet3, S Guillaume3, S Lancrenon4, P-M Llorca5. 1. CHU Clermont-Ferrand, EA U7280, Université d'Auvergne, Clermont-Ferrand, France. Electronic address: lsamalin@chu-clermontferrand.fr. 2. CHU Caremeau, Nîmes, France. 3. CHRU Montpellier, INSERM U1061, Université de Montpellier, Montpellier, France. 4. Sylia-Stat, Bourg-la-Reine, France. 5. CHU Clermont-Ferrand, EA U7280, Université d'Auvergne, Clermont-Ferrand, France.
Abstract
BACKGROUND: Compliance is often partial with oral antipsychotics and underestimated for patients with serious mental illness. Despite their demonstrated advantages in terms of relapse prevention, depot formulations are still poorly used in routine. As part of a process to improve the quality of care, French Association for Biological Psychiatry and Neuropsychopharmacology (AFPBN) Task Force elaborated a Formal Consensus for the prescription of depot antipsychotics in clinical practice. METHODS: The Task Force recommends as first-line choice, the use of long-acting injectable (LAI) second-generation antipsychotics in patients with schizophrenia, schizoaffective disorder and delusional disorder. They can be considered as a second-line option as a monotherapy to prevent manic recurrence or in combination with mood stabilizer to prevent depressive recurrence in the maintenance treatment of bipolar disorder. LAI second-generation antipsychotics can also be used after a first episode of schizophrenia. Depot neuroleptics are not recommended during the early course of schizophrenia and are not appropriate in bipolar disorder. They are considered as a second-line option for maintenance treatment in schizophrenia. RESULTS: LAI formulations should be systematically proposed to any patients for whom maintenance antipsychotic treatment is indicated. LAI antipsychotics can be used preferentially for non-compliant patients with frequent relapses or aggressive behaviors. CONCLUSION: A specific information concerning the advantages and inconveniences of the LAI formulations, in the framework of shared-decision making must be delivered to each patient. Recommendations for switching from one oral/LAI form to another LAI and for using LAI antipsychotics in specific populations (pregnant women, elderly patients, subjects in a precarious situation, and subjects having to be treated in a prison establishment) are also proposed.
BACKGROUND: Compliance is often partial with oral antipsychotics and underestimated for patients with serious mental illness. Despite their demonstrated advantages in terms of relapse prevention, depot formulations are still poorly used in routine. As part of a process to improve the quality of care, French Association for Biological Psychiatry and Neuropsychopharmacology (AFPBN) Task Force elaborated a Formal Consensus for the prescription of depot antipsychotics in clinical practice. METHODS: The Task Force recommends as first-line choice, the use of long-acting injectable (LAI) second-generation antipsychotics in patients with schizophrenia, schizoaffective disorder and delusional disorder. They can be considered as a second-line option as a monotherapy to prevent manic recurrence or in combination with mood stabilizer to prevent depressive recurrence in the maintenance treatment of bipolar disorder. LAI second-generation antipsychotics can also be used after a first episode of schizophrenia. Depot neuroleptics are not recommended during the early course of schizophrenia and are not appropriate in bipolar disorder. They are considered as a second-line option for maintenance treatment in schizophrenia. RESULTS: LAI formulations should be systematically proposed to any patients for whom maintenance antipsychotic treatment is indicated. LAI antipsychotics can be used preferentially for non-compliant patients with frequent relapses or aggressive behaviors. CONCLUSION: A specific information concerning the advantages and inconveniences of the LAI formulations, in the framework of shared-decision making must be delivered to each patient. Recommendations for switching from one oral/LAI form to another LAI and for using LAI antipsychotics in specific populations (pregnant women, elderly patients, subjects in a precarious situation, and subjects having to be treated in a prison establishment) are also proposed.
Authors: G Fond; O Godin; L Boyer; F Berna; M Andrianarisoa; N Coulon; L Brunel; E Bulzacka; B Aouizerate; D Capdevielle; I Chereau; T D'Amato; C Dubertret; J Dubreucq; C Faget; S Leignier; C Lançon; J Mallet; D Misdrahi; C Passerieux; R Rey; A Schandrin; M Urbach; P Vidailhet; P M Llorca; F Schürhoff; M Leboyer Journal: Eur Arch Psychiatry Clin Neurosci Date: 2018-05-28 Impact factor: 5.270
Authors: D Bennabi; T Charpeaud; A Yrondi; J-B Genty; S Destouches; S Lancrenon; N Alaïli; F Bellivier; T Bougerol; V Camus; J-M Dorey; O Doumy; F Haesebaert; J Holtzmann; C Lançon; M Lefebvre; F Moliere; I Nieto; C Rabu; R Richieri; L Schmitt; F Stephan; G Vaiva; M Walter; M Leboyer; W El-Hage; P-M Llorca; P Courtet; B Aouizerate; E Haffen Journal: BMC Psychiatry Date: 2019-08-28 Impact factor: 3.630
Authors: D Bennabi; A Yrondi; T Charpeaud; J-B Genty; S Destouches; S Lancrenon; N Allaili; F Bellivier; T Bougerol; V Camus; O Doumy; J-M Dorey; F Haesebaert; J Holtzmann; C Lançon; M Lefebvre; F Moliere; I Nieto; C Rabu; R Richieri; L Schmitt; F Stephan; G Vaiva; M Walter; M Leboyer; W El-Hage; B Aouizerate; E Haffen; P-M Llorca; P Courtet Journal: BMC Psychiatry Date: 2019-01-30 Impact factor: 3.630